Clinical trial

Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)

NCT03050866

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2017-02-21

PhasePHASE2

Study timeline

Study start (actual)2017-02-21Date precision: day

Registry last updated2021-08-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Circulating Tumor Cellunresolved

Metastatic Prostate Cancerunresolved

Interventions

CabazitaxelDRUG · verified · RxNorm: cabazitaxel

AntihistamineOTHER

CorticosteroidOTHER

H2 antagonistOTHER

AntiemeticOTHER

Sponsors & collaborators

Erasmus Medical Centerlead sponsor

Sanoficollaborator

Mapped research locations

RotterdamNetherlands3 NijmegenNetherlands1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03050866 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.